NVNO vs. TLSI, PROF, LUCD, CATX, SKIN, SGHT, OBIO, INFU, KRMD, and MGRM
Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include TriSalus Life Sciences (TLSI), Profound Medical (PROF), Lucid Diagnostics (LUCD), Perspective Therapeutics (CATX), Beauty Health (SKIN), Sight Sciences (SGHT), Orchestra BioMed (OBIO), InfuSystem (INFU), KORU Medical Systems (KRMD), and Monogram Orthopaedics (MGRM). These companies are all part of the "surgical & medical instruments" industry.
enVVeno Medical vs.
enVVeno Medical (NASDAQ:NVNO) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
enVVeno Medical has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.
TriSalus Life Sciences has a consensus target price of $11.56, suggesting a potential upside of 101.44%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than enVVeno Medical.
enVVeno Medical received 142 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 62.65% of users gave enVVeno Medical an outperform vote.
enVVeno Medical has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
In the previous week, TriSalus Life Sciences' average media sentiment score of 1.29 beat enVVeno Medical's score of 0.63 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.
enVVeno Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -206.24%. TriSalus Life Sciences' return on equity of 0.00% beat enVVeno Medical's return on equity.
34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 16.0% of enVVeno Medical shares are owned by insiders. Comparatively, 32.8% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
TriSalus Life Sciences beats enVVeno Medical on 9 of the 17 factors compared between the two stocks.
Get enVVeno Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVNO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
enVVeno Medical Competitors List
Related Companies and Tools
This page (NASDAQ:NVNO) was last updated on 4/18/2025 by MarketBeat.com Staff
